Shukra Pharmaceuticals (524632) Q1 26/27 earnings summary

Executive summary

• Un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and reviewed by the Audit Committee and Board of Directors.

• Both standalone and consolidated results were subject to a limited review by statutory auditors, with no material misstatements identified.

Financial highlights

• Standalone revenue from operations for Q1 FY27 was ₹2,406.20 lakhs, up from ₹650.08 lakhs in Q1 FY26.

• Standalone net profit for Q1 FY27 was ₹1,502.98 lakhs, compared to ₹102.96 lakhs in Q1 FY26.

• Consolidated revenue from operations for Q1 FY27 was ₹2,406.20 lakhs, up from ₹650.08 lakhs in Q1 FY26.

• Consolidated net profit for Q1 FY27 was ₹1,295.85 lakhs, compared to ₹102.96 lakhs in Q1 FY26.

• Earnings per share (EPS) for Q1 FY27 stood at ₹0.34 (standalone) and ₹0.30 (consolidated), compared to ₹0.02 in Q1 FY26.

Outlook and guidance

• No investor complaints were received or pending as of June 30, 2026.

• The company continues to operate in two segments: Pharmaceuticals and MedTech, with the MedTech segment effective from October 1, 2025.